GlobeNewswire Inc | Feb 9, 2021 08:00AM EST

February 09, 2021

BOSTON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the developmentof novel treatments for fibrosis and cancer, today announced Hans Schambye, the Companys Chief Executive Officer, will participate in multiple upcoming investor conferences. Dr. Schambye and Jon Freve, the Companys Chief Financial Officer, will be available for 1x1 meetings with investors at all meetings. Details are as follows:

SVB Leerink 10th Annual Global Healthcare Conference Presenting on Wednesday, February 24, 2021 at 9:20 AM ET and hosting investor meetings on the same date

Credit Suisse London Global Healthcare Conference Hosting investor meetings Tuesday, March 2 through Thursday, March 4, 2021

Oppenheimer 31st Annual Healthcare Conference Presenting on Tuesday, March 16, 2021 at 8:00 AM ET and hosting investor meetings on the same date

A live webcast of the available presentations will be posted under the Investor section of the Companys website at www.galecto.com. A replay of each available presentation will be available for 30 days following the event.

About GalectoGalecto (NASDAQ: GLTO)is a clinical stage biotechnology company incorporated in theU.S.with advanced programs in fibrosis and cancer centered on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2, which play key roles in regulating fibrosis. The Companys pipeline includes our lead product candidate, which is an inhaled galectin-3 modulator currently in phase 2b for the potential treatment of idiopathic pulmonary fibrosis. Our pipeline also includes two additional assets about to move into phase 2 studies.

Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Galectos focus, plans for clinical development, product candidates and pipeline. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. For such statements, Galecto claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially fromGalecto'sexpectations. Factors that could cause actual results to differ materially from the forward-looking statements include risks and uncertainties related to the development of Galectos product candidates and their therapeutic potential, having adequate funds and their use, and those disclosed in Galectos filings with theSecurities and Exchange Commission. These forward-looking statements representGalecto'sjudgment as of the time of this release. Galecto disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

For more information, contact:

Galecto Inc. Hans Schambye, CEO Jon Freve, CFO+45 70 70 52 10

Investors/US Media/EUAshley R. Robinson Mary-Ann Changarr@lifesciadvisors.com mchang@lifesciadvisors.com+1 617 775 5956 +44 7483 284 853